BlackRock, Inc. 13D and 13G filings for Nektar Therapeutics:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-04-17 09:35 am Sale |
2025-03-31 | 13G | Nektar Therapeutics NKTR |
BlackRock Inc. BLK |
12,528,006 6.700% |
-3,441,339 (-21.55%) |
Filing |
| 2024-11-08 5:31 pm Unchanged |
2024-09-30 | 13G | Nektar Therapeutics NKTR |
BlackRock Inc. BLK |
15,969,345 8.700% |
0 (Unchanged) |
Filing |
| 2024-10-22 3:24 pm Purchase |
2024-09-30 | 13G | Nektar Therapeutics NKTR |
BlackRock Inc. BLK |
15,969,345 8.700% |
7,365,023 (+85.60%) |
Filing |
| 2023-07-07 4:35 pm Sale |
2023-06-30 | 13G | Nektar Therapeutics NKTR |
BlackRock Inc. BLK |
8,604,322 4.500% |
-9,696,352 (-52.98%) |
Filing |
| 2023-05-05 11:52 am Sale |
2023-04-30 | 13G | Nektar Therapeutics NKTR |
BlackRock Inc. BLK |
18,300,674 9.700% |
-17,627,419 (-49.06%) |
Filing |
| 2023-01-23 3:52 pm Purchase |
2022-12-31 | 13G | Nektar Therapeutics NKTR |
BlackRock Inc. BLK |
35,928,093 19.100% |
9,256,290 (+34.70%) |
Filing |
| 2022-01-27 1:59 pm Unchanged |
2021-12-31 | 13G | Nektar Therapeutics NKTR |
BlackRock Inc. BLK |
26,671,803 14.500% |
0 (Unchanged) |
Filing |
| 2022-01-25 6:45 pm Purchase |
2021-12-31 | 13G | Nektar Therapeutics NKTR |
BlackRock Inc. BLK |
26,671,803 14.500% |
8,293,723 (+45.13%) |
Filing |
| 2021-01-26 6:52 pm Sale |
2020-12-31 | 13G | Nektar Therapeutics NKTR |
BlackRock Inc. BLK |
18,378,080 10.200% |
-39,455 (-0.21%) |
Filing |